SEHK:2171Biotechs
Assessing CARsgen Therapeutics Holdings’s Valuation After Full Year 2025 Results And Narrowed Net Loss
CARsgen Therapeutics Holdings (SEHK:2171) moved after releasing full year 2025 results, reporting sales of CN¥125.66 million and a net loss of CN¥97.86 million, along with updated corporate governance proposals announced the same day.
See our latest analysis for CARsgen Therapeutics Holdings.
The earnings release and governance proposals arrived after a firm 27.64% 1 year total shareholder return. The 30 day and 90 day share price returns of 4.18% and 4.67% suggest momentum has been building...